Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
USD 36.0
(-7.98%)
USD 36.0
(-7.98%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -5.73 USD | 55.06% |
| 2022 | -12.75 USD | -113.57% |
| 2021 | -5.97 USD | -80.36% |
| 2020 | -3.31 USD | 69.66% |
| 2019 | -10.91 USD | 0.0% |
| 2017 | - USD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -3.64 USD | -65.45% |
| 2024 Q1 | -2.20 USD | -21.55% |
| 2023 Q2 | -1.32 USD | -28.16% |
| 2023 FY | - USD | 55.06% |
| 2023 Q1 | -1.03 USD | 68.79% |
| 2023 Q3 | -1.50 USD | -13.64% |
| 2023 Q4 | -1.81 USD | -20.67% |
| 2022 Q1 | -2.71 USD | -86.9% |
| 2022 FY | - USD | -113.57% |
| 2022 Q4 | -3.30 USD | -88.57% |
| 2022 Q3 | -1.75 USD | 69.14% |
| 2022 Q2 | -5.67 USD | -109.23% |
| 2021 Q4 | -1.45 USD | 4.61% |
| 2021 Q1 | -4.27 USD | 0.0% |
| 2021 Q2 | -3.23 USD | 24.36% |
| 2021 Q3 | -1.52 USD | 52.94% |
| 2021 FY | - USD | -80.36% |
| 2020 Q2 | -3.08 USD | -0.33% |
| 2020 FY | - USD | 69.66% |
| 2020 Q3 | -3.27 USD | -6.17% |
| 2020 Q1 | -3.07 USD | -98932.26% |
| 2019 Q1 | -1.41 USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q4 | -0.00 USD | 99.85% |
| 2019 Q3 | -2.04 USD | 56.32% |
| 2019 Q2 | -4.67 USD | -231.21% |
| 2018 Q3 | -1.53 USD | -51.49% |
| 2018 Q1 | -2.32 USD | -184.27% |
| 2018 Q2 | -1.01 USD | 56.47% |
| 2017 Q2 | -1.48 USD | -3.5% |
| 2017 Q3 | -1.19 USD | 19.59% |
| 2017 Q4 | 2.75 USD | 331.34% |
| 2017 Q1 | -1.43 USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| ADC Therapeutics SA | -2.94 USD | -94.898% |
| Alto Neuroscience, Inc. | -1.35 USD | -324.444% |
| Annovis Bio, Inc. | -6.23 USD | 8.026% |
| Ginkgo Bioworks Holdings, Inc. | -18.37 USD | 68.808% |
| Nuvation Bio Inc. | -0.35 USD | -1537.143% |
| Nuvation Bio Inc. | -0.35 USD | -1537.143% |
| Arcus Biosciences, Inc. | -4.15 USD | -38.072% |
| Theriva Biologics, Inc. | -28.49 USD | 79.888% |
| Zymeworks Inc. | -1.72 USD | -233.14% |